Recursion Pharmaceuticals, Inc. (NASDAQ: RXRX), a clinical-stage TechBio company, announced on March 25, 2026, that Vicki Goodman, M.D., will take over as Chief Medical Officer (CMO) effective April 6, 2026. This transition comes as David Mauro, M.D., Ph.D., steps down from the role after approximately three years but will remain with the company in an advisory capacity until May 29, 2026. Dr. Goodman brings extensive experience in oncology and clinical development, having previously served as CMO at Mural Oncology and held senior roles at Exelixis and Merck. Her appointment is seen as a strategic move to enhance Recursion's clinical pipeline as the company prepares for key clinical and regulatory milestones. The leadership change is expected to positively impact the company's operational execution and strategy outlook, particularly in advancing its investigational medicines across various therapeutic areas. Dr. Goodman expressed enthusiasm about joining Recursion at a pivotal moment, emphasizing the company's unique integration of scientific and technological rigor in drug discovery and development. The leadership transition is anticipated to facilitate disciplined development decisions and support the delivery of impactful therapies to patients.

Press Release distribution

National Press Distribution across U.S. Media. Direct Access to Key Decision Making Editors.